You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell lines
|
|---|---|
| Published in |
BMC Pharmacology and Toxicology, March 2013
|
| DOI | 10.1186/2050-6511-14-18 |
| Pubmed ID | |
| Authors |
Panagiotis Apostolou, Maria Toloudi, Marina Chatziioannou, Eleni Ioannou, Dennis R Knocke, Joe Nester, Dimitrios Komiotis, Ioannis Papasotiriou |
| Abstract |
BACKGROUND: Platinum derivatives are used widely for the treatment of many cancers. However, the toxicity that is observed makes imperative the need for new drugs, or new combinations. AnvirzelTM is an extract which has been demonstrated with experimental data that displays anticancer activity. The aim of the present study is to determine whether the combination of Cisplatin and AnvirzelTM has a synergistic effect against different types of cancer.Materials and methods: To measure the efficacy of treatment with Cisplatin and AnvirzelTM, methyl-tetrazolium dye (MTT) chemosensitivity assays were used incorporating established human cancer cell lines. Measurements were performed in triplicates, three times, using different incubation times and different concentrations of the two formulations in combination or on their own. t-test was used for statistical analysis. RESULTS: In the majority of the cell lines tested, lower concentrations of AnvirzelTM induced a synergistic effect when combined with low concentrations of Cisplatin after an incubation period of 48 to 72 h. The combination of AnvirzelTM/Cisplatin showed anti-proliferative effects against a wide range of tumours. CONCLUSION: The results showed that the combination of AnvirzelTM and Cisplatin is more effective than monotherapy, even when administered at low concentrations; thus, undesirable toxic effects can be avoided. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Greece | 1 | 2% |
| Kenya | 1 | 2% |
| Unknown | 51 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 12 | 22% |
| Student > Master | 8 | 15% |
| Researcher | 6 | 11% |
| Student > Ph. D. Student | 5 | 9% |
| Student > Doctoral Student | 4 | 7% |
| Other | 6 | 11% |
| Unknown | 13 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 13 | 24% |
| Agricultural and Biological Sciences | 12 | 22% |
| Chemistry | 5 | 9% |
| Medicine and Dentistry | 3 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Other | 5 | 9% |
| Unknown | 14 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 August 2020.
All research outputs
#7,993,558
of 24,733,536 outputs
Outputs from BMC Pharmacology and Toxicology
#140
of 469 outputs
Outputs of similar age
#65,262
of 201,694 outputs
Outputs of similar age from BMC Pharmacology and Toxicology
#7
of 12 outputs
Altmetric has tracked 24,733,536 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 469 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 201,694 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.